Cytotoxicity Testing For Medical Devices
Cytotoxicity testing for medical devices investigates whether a finished device, its materials or substances released from it can harm cultured mammalian cells. It is an in vitro screening endpoint, not a certificate of whole-device biological safety. Before requesting a quotation, define what contacts the patient, how the sample represents production and which evidence the reviewer needs.
1. Decide whether cytotoxicity evidence is relevant
Start with intended use, direct or indirect body contact, contact site, duration, composition, processing and existing biological evidence. ISO 10993-1:2025 provides the biological-risk evaluation framework; ISO 10993-5:2009 defines cytotoxicity methods. Neither makes an identical test package compulsory for every product. Document the rationale for testing, using existing information or addressing the endpoint another way.
For EU devices, MDR Annex I, sections 10.1–10.2, addresses biological compatibility and contaminants/residues. For US submissions, assess the applicable FDA guidance and the FDA-recognized edition and scope of each standard; the September 2023 FDA guidance still uses the earlier ISO 10993-1 framework, while the FDA also recognizes ISO 10993-1:2025 with a partial recognition. A test result is evidence within a risk assessment, not marketing authorization. For the wider endpoint strategy, see ISO 10993 biocompatibility testing.
2. Select the assay: a method-to-decision matrix
ISO 10993-5 describes extract, direct-contact and indirect-contact approaches. Ask the laboratory to explain how the chosen exposure route reflects the device and how the cell response is scored.
| Route | When to consider it | Question for the laboratory |
|---|---|---|
| Extract / elution | Leachable substances, processing residues or complex shapes warrant exposure through a prepared liquid extract. | Which extraction medium, conditions, ratio and qualitative or quantitative viability readout are justified? |
| Direct contact | The finished surface can be placed on a cell layer without invalidating the assay. | How will sample geometry, pressure and the contact area be controlled? |
| Indirect contact / diffusion | Direct placement is impractical and migrating substances can reach cells through a barrier. | Can the substance diffuse through the chosen barrier, and what might the method miss? |
A negative result covers only the method, samples and conditions tested. A positive cytotoxic response requires investigation; it does not independently prove clinical harm. The assay does not replace irritation, sensitization, chemical characterization or other relevant endpoints.
3. Lock the sample and extraction plan before dispatch
ISO 10993-12:2021, including Amendment 1:2025, addresses representative samples, controls and extraction preparation. Agree a written sample plan; do not select quantities or extraction settings from an unrelated device's report.
- Representativeness: list every patient-contacting material, coating, adhesive and relevant component; justify testing whole devices, parts or worst-case variants.
- Manufacturing state: identify final curing, cleaning, additives, process aids, packaging and sterilization; record whether the sample is the final marketed configuration.
- Exposure design: have the laboratory justify media, surface-area/mass-to-volume ratio, time, temperature and whether multiple extracts are needed.
- Controls and logistics: confirm positive/negative controls, blank extracts, replicate strategy, sample count, shipping and traceable lot IDs.
- Traceability: retain drawings, bill of materials, batch records, sterilization status, deviations and sample-to-report mapping.
Testing a convenient prototype may be useful for development but may not substantiate a claim about a later sterile, coated or differently processed product.
4. Check laboratory competence and report usability
Before placing an order, request the laboratory's proposed protocol and report outline, then verify:
- Method and scope: exact ISO 10993-5 assay, applicable edition, extraction under ISO 10993-12 and the target market's expectations.
- Accreditation: current ISO/IEC 17025 accreditation certificate and its scope covering the actual method, not merely a laboratory-wide logo.
- US ASCA, if relevant: whether the specific method is in the laboratory's current FDA ASCA scope and whether its ASCA status is active; ASCA is voluntary, not a universal prerequisite.
- Report content: device/sample identification, preparation, controls, exposure settings, validity criteria, observed response, deviations, signed conclusions and underlying data availability.
- Acceptance path: which reviewer will use it, whether a declaration of conformity is contemplated, and whether translation or supplemental justification is required.
FDA's test-report guidance makes sample preparation, test parameters, result analysis and conclusions particularly important. Confirm report ownership, revision control and access to raw data before committing.
5. Can a previous cytotoxicity report be reused?
Reuse is an evidence-bridging decision, not a rule that results expire after a fixed period. Compare the previous test article and current device against a documented change history.
| Scenario | Potential route | Evidence to retain |
|---|---|---|
| Same final design and manufacturing process | Consider reuse, subject to the applicable review and documented rationale. | Old report, traceable sample/lot, unchanged specifications and process history. |
| New supplier or grade, coating, adhesive, sterilization or cleaning | Reassess whether chemical or biological exposure has changed; targeted testing may be needed. | Material/process comparison, risk evaluation, extractables data where relevant and test justification. |
| Report covers only raw resin or an unprocessed prototype | Do not assume it covers the finished marketed device. | Gap analysis for additives, processing residues, interfaces and final configuration. |
A passing supplier certificate alone is not a substitute for a device-specific biological evaluation.
6. Investigate failures and define retest triggers
If a test indicates cytotoxicity, preserve the raw result and examine controls, assay validity, extraction medium, pH/osmolality effects, sample contamination, manufacturing residues and material formulation. Do not simply dilute extracts or repeatedly test until a passing result appears without scientific justification.
- Invalid assay or control failure: correct the methodological issue and repeat under an approved protocol.
- Valid adverse response: investigate the source, assess biological relevance and decide on mitigation, redesign or justified further evidence.
- Design/material/process change: compare its potential effect on patient exposure and decide whether existing data still cover the device.
- Sterilization, packaging or cleaning change: reassess residuals and final-state representativeness; re-extraction or retesting may be appropriate.
Document the decision, responsible reviewer and approved change-control record; neither automatic retesting nor automatic acceptance is defensible for every change.
7. Five questions to settle before booking
Ask the manufacturer and laboratory to agree on: (1) exact device/contact and intended market; (2) rationale for this endpoint and selected assay; (3) finished representative sample, quantity and extraction conditions; (4) required laboratory accreditation/ASCA scope and report deliverables; and (5) how prior results, failures and future design changes will be evaluated. If any answer is unresolved, request a written feasibility review before dispatching samples.
This article owns the cytotoxicity evidence decision; it does not reproduce full registration procedures. For practical provider selection see product testing laboratories; for a wider biological evaluation plan see ISO 10993 biocompatibility testing.
Frequently asked questions
Must every patient-contacting medical device undergo a new cytotoxicity test?
No blanket conclusion follows from contact alone. Identify the applicable biological endpoint, relevant market expectations and usable prior evidence; document why a new assay is or is not needed.
May I test a nonsterile prototype when the marketed device will be sterile?
It may support development, but it may not represent sterilization residues or final processing. Agree what final-state evidence will bridge that difference.
Does a passing cytotoxicity result establish full biocompatibility?
No. It addresses one cellular response under specified test conditions, not all biological hazards or clinical performance.
Is an old raw-material or supplier report enough?
Not by itself. Evaluate the composition, supplier changes, coatings, processing, final sterilization and contact exposure of the actual device.
What should I do after a valid cytotoxic result?
Keep the report, investigate method and materials with the laboratory, evaluate patient relevance and decide on corrective action and any justified retesting; do not suppress the result.
Official technical and regulatory references
Use the current applicable editions and jurisdiction-specific recognition details: ISO 10993-5 — in vitro cytotoxicity; ISO 10993-1:2025 — biological-risk evaluation; ISO 10993-12 amendment; FDA biocompatibility guidance; FDA ASCA programme; EU MDR, Annex I.